Imunon (IMNN) Return on Capital Employed (2011 - 2026)
Imunon's (IMNN) quarterly Return on Capital Employed came in at 247.39% in Q1 2026, up 48536.0% YoY from N/an in Q1 2025, and down 1.56% on a QoQ basis from 243.61% in Q4 2025.
Imunon (IMNN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Imunon (IMNN) has 16 years of Return on Capital Employed data on file, last reported at 247.39% in Q1 2026.
- Quarterly Return on Capital Employed rose 48536.0% year-over-year to 247.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 247.39% (up 48536.0% YoY) and the FY2025 annual result came in at 229.67%, down 5624.0% from the prior year.
- Return on Capital Employed slipped to 247.39% in Q1 2026, from 243.61% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.25% in Q1 2022 to a low of 732.75% in Q1 2025.
- A 5-year average of 204.77% and a median of 132.31% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 57974 bps — and 2026, when it jumped 48536 bps.
- Tracing IMNN's Return on Capital Employed over 5 years: stood at 59.03% in 2022, then tumbled by 124 bps to 132.31% in 2023, then sank by 117 bps to 287.07% in 2024, then advanced by 15 bps to 243.61% in 2025, then declined by 2 bps to 247.39% in 2026.
- The last three Return on Capital Employed figures came in at 247.39% (Q1 2026), 243.61% (Q4 2025), and 309.91% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 7.88% |
| 10 | Imunon | 8.50 Mn | 8.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -247.39% |
| Dec 31, 2025 | -243.61% |
| Sep 30, 2025 | -309.91% |
| Jun 30, 2025 | -638.81% |
| Mar 31, 2025 | -732.75% |
| Jun 30, 2024 | -287.07% |
| Mar 31, 2024 | -153.01% |
| Dec 31, 2023 | -132.31% |
| Sep 30, 2023 | -102.89% |
| Jun 30, 2023 | -82.83% |
| Mar 31, 2023 | -75.91% |
| Dec 31, 2022 | -59.03% |
| Sep 30, 2022 | -4.00% |
| Jun 30, 2022 | -1.84% |
| Mar 31, 2022 | -0.25% |
| Dec 31, 2021 | 0.43% |
| Sep 30, 2021 | -27.17% |
| Jun 30, 2021 | -26.72% |
| Mar 31, 2021 | -39.31% |
| Dec 31, 2020 | -60.32% |